Evidence map›Paper›PMID 26685681›Full record

ReviewCurrent pharmaceutical design2016

Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.

David S Hersh, Aniket S Wadajkar, Nathan Roberts, Jimena G Perez, Nina P Connolly, Victor Frenkel, Jeffrey A Winkles, Graeme F Woodworth, Anthony J Kim

Abstract readReview
In one paragraph

Review in Current pharmaceutical design, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. [Research progress of different types of stem cells in treatment of ischemic stroke].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2021
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Nano-Based Technology in Glioblastoma.Molecules (Basel, Switzerland) · 2025
    Review

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

David S Hersh *Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201 (USA).
Aniket S Wadajkar *Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201 (USA).
Nathan RobertsDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201 (USA).
Jimena G PerezDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201 (USA).
Nina P ConnollyDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201 (USA).
Victor FrenkelMarlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201 (USA).
Jeffrey A WinklesMarlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201 (USA).
Graeme F WoodworthDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201 (USA).
Anthony J KimDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201 (USA).

Funding

EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9M
Transitioning Early Career Neurosurgeons to Scientific IndependenceK12NS080223 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ESKANDAR, EMAD N · 2012 to 2022
$9.2M
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
T32: Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer ResearchT32CA153952 · NCI · JOHNS HOPKINS UNIVERSITY · PI Denis Wirtz · 2015 to 2026
$3.5M
T-32 NIH Postdoctoral Training Program in Nanotechnology for Cancer Medicine NTCMT32CA130840 · NCI · JOHNS HOPKINS UNIVERSITY · PI WIRTZ, DENIS · 2008 to 2012
$1.2M
Brain-Penetrating Nanoparticle Therapeutics for Invasive Brain CancerK08NS090430 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI WOODWORTH, GRAEME F · 2014 to 2018
$748k
Fn14-targeted Therapeutics for Invasive Brain CancerK25EB018370 · NIBIB · UNIVERSITY OF MARYLAND BALTIMORE · PI KIM, ANTHONY J. · 2014 to 2016
$390k
NCI NIH HHS T32 CA130840NCI NIH HHS T32 CA153952NCI NIH HHS T32 CA154274NIBIB NIH HHS K25 EB018370NIBIB NIH HHS K25EB018370NIGMS NIH HHS R25 GM055036NINDS NIH HHS K08NS09043NINDS NIH HHS K08 NS090430NINDS NIH HHS K12 NS080223NINDS NIH HHS K12NS080223
6 · The paper itself

Abstract

The blood-brain barrier (BBB) poses a unique challenge for drug delivery to the central nervous system (CNS). The BBB consists of a continuous layer of specialized endothelial cells linked together by tight junctions, pericytes, nonfenestrated basal lamina, and astrocytic foot processes. This complex barrier controls and limits the systemic delivery of therapeutics to the CNS. Several innovative strategies have been explored to enhance the transport of therapeutics across the BBB, each with individual advantages and disadvantages. Ongoing advances in delivery approaches that overcome the BBB are enabling more effective therapies for CNS diseases. In this review, we discuss: (1) the physiological properties of the BBB, (2) conventional strategies to enhance paracellular and transcellular transport through the BBB, (3) emerging concepts to overcome the BBB, and (4) alternative CNS drug delivery strategies that bypass the BBB entirely. Based on these exciting advances, we anticipate that in the near future, drug delivery research efforts will lead to more effective therapeutic interventions for diseases of the CNS.

Indexed as

Drug Delivery SystemsAnimalsBlood-Brain BarrierBrain DiseasesCentral Nervous System AgentsHumansCentral Nervous System Agents

Identifiers

PMID26685681
PMCPMC4900538

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.